![]() The scheme gives tech founders and entrepreneurs access to the resources and infrastructure they need to succeed, including full use of the facilities at Department Bonded Warehouse, a network of like-minded entrepreneurs, mentoring from business experts and funding opportunities. Several of the ambitious early-stage tech companies already have impressive achievements, partnerships and products under their belts, and are now set on reaching new heights with the support of Exchange and its community. The businesses, which operate across the FinTech, EdTech and e-commerce sectors, amongst others, form the second cohort of Exchange, the support programme based at Department Bonded Warehouse in the tech, digital and creative city-centre cluster, Enterprise City. 30 firms selected to join Enterprise City’s Exchange start-up support schemeģ0 early-stage businesses have been selected to take part in the second intake of a unique start-up support programme, establishing the next generation of Manchester’s trailblazing tech firms. Winning approval from the FDA and launching our first product in the United States.Next generation of start-ups driving tech innovation in Manchester announced. Visit scientific meetings, conferences and trade shows to tell your story. Phil McCaw, managing partner of Movac, is also a director, with chairman Jim McLean, former executive director of Genesis Research. With the prospect of being a $50 million company in a few years, Ward says his board is providing him with valuable advice. One of Mesynthes’ directors is Mark Ahn, head of Nasdaq-listed Galena Biopharma. A US office and float are also possible, Ward says. Ward and his team are also finalising plans for new premises up to five times bigger than those they occupy at present. “At the moment we are in the process of working through that.” Meanwhile, a float is being considered among other options. The company is currently raising $5 million to fund growth.īusiness growth has been 50 to 100 per cent a year and Ward expects revenue to double over the next two to three years. Mesynthes’ shareholders include management and investors such as Movac, Sparkbox, K1W1 and NZ Venture Investment Fund. “We could easily go from 30 to 40 people in the next year,” says Ward. It now has 20 staff, mainly developmental scientists, and will be expanding the sales and marketing side of the business. Ward, a former veterinarian and head of NZBio, started Mesynthes in February 2008. “What we have done is focus on proving the technology, ensuring we have the data to prove the claims.” Spending time and money on finding partners has been important. Then, on the back of our relationship with Hollister, we have worked with key opinion leaders – leading physicians and academics,” he says. “Initially we did some clinical work with US doctors. Ward says he has worked hard at building support from top academics and surgeons in the field and the New Zealand product has some unique qualities in terms of usability and strength. Mesynthes’ US sales go through Hollister, a US multi-wound care company with which it has a nationwide distribution and marketing deal. “We use that to fabricate a range of products,” says founder and chief executive Brian Ward. ![]() “We are taking a product that comes out of the meat industry – tissue derived from the sheep forestomach – taking a particular layer of that tissue and treating it so that it encourages tissue regeneration and the human body does not react to it. Mesynthes is also developing implantable regenerative tissue substitutes suitable for a wide range of soft-tissue reinforcement and repair applications such as hernia repair and breast reconstruction. Its first product, Endoform Dermal Template (EDT), gained clearance from the United States Food and Drug Administration in January 2010 and is now being distributed through a US partner. ![]() The American market has 20 million diabetes sufferers and Wellington-based regenerative medicine company Mesynthes (pronounced Messinthis) makes a wound care product that is ideal for chronic conditions such as ulcers, a nasty diabetes side-effect. How do you make a successful export product? Give the people what they need. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |